Modified analogs of lipid lowering drugs were found to lower both glucose and insulin levels in rodent models of type 2 diabetes (Sohda et al. 1984, 1990, 2002) secondary to improved insulin sensitivity (Hofmann and Colca, 1992; Owens, 2002). The gene discussed is INS; the disease is type 2 diabetes mellitus.